The world's first new coronavirus and antibody kit was born

the body is immune to the new coronavirus, it's an hour to know. Reporter 4 from Nanjing Kingsley Biotech Co. , Ltd. was informed that the company and Duke - National University of Singapore School of Medicine, Singapore Science and Technology Research Bureau under the Medical Diagnostic Development Center jointly developed the world's first new coronavirus and anti-medical test kit, no need to use the real virus to carry out experiments, nor in the P3 laboratory testing, an hour can produce results.
when pathogenic microorganisms invade, the body produces corresponding antibodies. Pathogenic microorganisms invade cells by binding specific molecules expressed by the pathogen itself to the cell's binding to the cell's binding to infect the cells and further amplification. The median antibody is certain antibodies produced by B lymphocytes that bind to antigens on the surface of the pathogenic microorganism, thereby preventing the pathogenic microorganism from clinging to the target cell subject and preventing the invasion of the cell.
Currently, based on the new coronavirus's mesothcoming experiments, live viruses, cells, and skilled operators are required, with complex laboratory procedures, low sensitivity and 2 to 3 days to produce results. In contrast, this kit can be tested quickly within an hour in most studies or clinical laboratories, with high-volume and fully automated testing.
" Kits developed by our team can be used for contact tracking, finding intermediate hosts, population immunity, protective immunity effectiveness, and evaluation of vaccine efficacy without biosecurity measures that are easily accessible to the global community, including many developing countries. Wang Linfa, the main researcher on the kit and director of the National University of Singapore's Key Research Program on Ingdo Infectious Diseases, said.
" is a unique and innovative serological testing system with the advantages of high sensitivity, specificity and application to all antibody subtypes. Dr. Zhu Li, chief strategy officer of Kingsley, told reporters that the test results could help local governments guide the resumption of work.